Weight LossHormonesSubcutaneous

Tirzepatide

Typical Dose

2.5–15 mg

Frequency

Weekly

Half-Life

~5 days

Research-use dosing; specific study population not established.

Tirzepatide Overview

Mechanism of Action

Tirzepatide is a dual GIP and GLP-1 receptor agonist that enhances insulin secretion, suppresses appetite, slows gastric emptying, and promotes weight loss through complementary metabolic pathways.

Half-Life

~5 days

Timing

Same day each week

Alternatives in this class

Same mechanism as Tirzepatide — use as an alternative, not combined together.

  • Semaglutide
  • Retatrutide

Common Stacks

  • B12

Tirzepatide Dosing Protocol

Titration

2.5 mg/week for 4 weeks, then increase

Maintenance

5-15 mg/week

Tirzepatide Expected Timeline

No timeline data available.

Tirzepatide Side Effects

Nausea

Diarrhea

Decreased appetite

Injection site reactions

Constipation

Tirzepatide Research Studies

No studies referenced.

Tirzepatide FAQ

How is Tirzepatide different from Semaglutide?

Tirzepatide targets both GIP and GLP-1 receptors, while Semaglutide targets only GLP-1.

Related Protocols